Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations

摘要: Aim of this study is to investigate the capability Imatinib induce an anti-leukemic effect in Core Binding Factor (CBF)-leukemia patients presenting either with extracellular juxtamembrane or kinase KIT mutations. On basis a screening analysis for mutations, two mutation and one mutation, first subsequent leukemic relapse, received 400 mg twice daily 30 days. After discontinuation, bone marrow cells were re-tested assess mutational status chromosomal set. In our experience, none treated had response by standard criteria; particular, we did not observe any activity against acute myeloid leukemia (AML) associated However, patient seems have some clinical beneficial and, most important, able abrogate subclone carrying mutation. Whether Imatinib, combination other agents, may play role treatment AML more sensitive remains be determined.